New drug combo aims to fight deadly gallbladder cancer

NCT ID NCT07099547

Recruiting now Disease control Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether adding an experimental immunotherapy drug called ZG005 to standard chemotherapy (gemcitabine and cisplatin) can help people with advanced gallbladder cancer. About 60 participants will receive either the combination or standard treatment. The study is currently recruiting and will measure how well tumors respond and what side effects occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZG005 (an experimental immunotherapy) combined with gemcitabine and cisplatin chemotherapy
What this could lead to: If successful, this could offer a more effective first-line treatment option for advanced gallbladder cancer, potentially shrinking tumors and extending life.
What could go wrong: This is an early Phase 2 study with only 60 participants, so results are preliminary. The combination may cause significant side effects, and it is not yet known if it works better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GALLBLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bile duct carcinoma biliary tract cancer gallbladder cancer gallbladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CARCINOMA

Contacts and locations

Locations

The First Affiliated Hospital of University of Science and Technology of China
RECRUITING

Hefei, Anhui, 230001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.